RT Journal Article
SR Electronic
T1 Transcriptomic signatures associated with regional cortical thickness changes in Parkinson’s disease
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.06.19.158808
DO 10.1101/2020.06.19.158808
A1 Keo, Arlin
A1 Dzyubachyk, Oleh
A1 van der Grond, Jeroen
A1 van Hilten, Jacobus J.
A1 Reinders, Marcel J. T.
A1 Mahfouz, Ahmed
YR 2020
UL http://biorxiv.org/content/early/2020/06/19/2020.06.19.158808.abstract
AB Cortical atrophy is a common manifestation in Parkinson’s disease, particularly in later disease stages. Here, we investigated patterns of cortical thickness using T1-weighted anatomical MRI data of 149 Parkinson’s disease patients and 369 controls. To elucidate the molecular underpinnings of cortical thickness changes in Parkinson’s disease, we performed an integrated analysis of brain-wide healthy transcriptomic data from the Allen Human Brain Atlas and neuroimaging features. For this purpose, we used partial least squares regression to identify gene expression patterns correlated with cortical thickness changes. In addition, we identified gene expression patterns underlying the relationship between cortical thickness and clinical domains of Parkinson’s disease. Our results show that genes whose expression in the healthy brain is associated with cortical thickness changes in Parkinson’s disease are enriched in biological pathways related to sumoylation, regulation of mitotic cell cycle, mitochondrial translation, DNA damage responses, and ER-Golgi traffic. The associated pathways were highly related to each other and all belong to cellular maintenance mechanisms. The expression of genes within most pathways was negatively correlated with cortical thickness changes, showing higher expression in regions associated with decreased cortical thickness (atrophy). On the other hand, sumoylation pathways were positively correlated with cortical thickness changes, showing higher expression in regions with increased cortical thickness (hypertrophy). Our findings suggest that alterations in the balanced interplay of these mechanisms play a role in changes of cortical thickness in Parkinson’s disease and possibly influence motor and cognitive functions.Competing Interest StatementThe authors have declared no competing interest.AHBAAllen Human Brain Atlas;CTcortical thickness;LEDlevodopa equivalent dose;MDS-UPDRSMovement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale;MMSEmini-mental state examination;PLSpartial least squares;SENS-PDseverity of non-dopaminergic symptoms in Parkinson’s disease